[1][2] Since the 1990s, the term "T7 supergroup" has been coined for the expanding group of bacteriophages related to coliphage T7, as members of the family Podoviridae.

[4] Some experiments suggest that Autographiviridae bacteriophages show promise in regulating and stifling the growth of infectious bacteria, like Klebsiella pneumoniae, in humans.

[7] For the past two decades, studying phage therapy has grown in popularity with major research centers opening up in the United States, Poland, Georgia, and Belgium.

In turn, many biotechnology companies have shifted their focus to phage therapy, with some like Armata Pharmaceuticals completely dedicating themselves to combating the problem of antibiotic resistance.

[14] Phage cocktails are most commonly used to combat infections caused by Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.

[15] Clinical practices have employed phage cocktails to prevent bacterial biofilm formation, which is one of the greatest challenges in the healthcare industry.

A recent study showed that formulated phage cocktails that included Autographiviridae under the now-abolished family classification Podoviridae, effectively reduced the growth of Klebsiella pneumoniae.

[13][11] The name of this family, termed Autographiviridae, refers to the “auto-graphein” or “self-transcribing” phages which encode their own (single subunit) RNA polymerase, a common characteristic among its members.

[1] The former family of Podoviridae, which contained many of the viruses that are now classified under Autographiviridae, was defined based on morphology and the presence of short noncontractile tails.